Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in stomach and esophageal cancer
- New trial Spotlight
Stomach and esophageal cancer
Phase 3 Zolbetuximab (CLDN18.2 mAb) trial in advanced gastric/GEJ cancer
This study compares zolbetuximab combined with pembrolizumab and chemotherapy versus placebo in adults with unresectable or metastatic stomach or GEJ adenocarcinoma that are HER2-negative, CLDN18.2-positive, and…
NCT06901531 Registrational - New trial Spotlight
Stomach and esophageal cancer
Phase 3 Study of Ifinatamab Deruxtecan, a B7-H3 directed Topo1 toxin ADC, in ESCC
Researchers at Daiichi Sankyo are assessing ifinatamab deruxtecan versus investigator’s choice chemotherapy in a randomized, open-label Phase 3 trial for patients with unresectable advanced or metastatic esophageal…
NCT06644781 Registrational - Trial result
Stomach and esophageal cancer
Avelumab + Trastuzumab/FOLFOX Posts 61% Early Response and 8 mo PFS in HER2‑Positive Metastatic G/GEJ Adenocarcinoma
Avelumab, an anti‑PD‑L1 IgG1, was paired with trastuzumab (HER2 antibody) plus mFOLFOX6 in the single‑arm phase II HCRN GI17‑319 study (NCT03783936). Eighteen previously untreated patients with HER2‑amplified…
NCT03783936 - New trial
Stomach and esophageal cancer
Phase II Trial of Ivonescimab, a PD‑1/VEGF bispecific antibody, with FOLFOX in advanced gastroesophageal adenocarcinoma
Massachusetts General Hospital sponsors this single-arm, open-label Phase II study evaluating the combination of ivonescimab and FOLFOX chemotherapy (including 5‑fluorouracil inhibiting thymidylate synthase,…
NCT07070466 Exploratory - New trial
Stomach and esophageal cancer
Phase II Trial: AZD0901 CLDN18.2 ADC and rilvegostomig Tigit/PD-1 bispecific mAb in gastroesophageal cancer
This trial evaluates safety, tolerability, pharmacokinetics, and early anti-tumor activity of perioperative combination treatments in patients with locally advanced resectable gastric, gastroesophageal junction, or…
NCT07069712 Exploratory - New trial
Stomach and esophageal cancer
Phase 3 Trial of Trastuzumab Deruxtecan, a HER2-directed topoisomerase I inhibitor ADC
This randomized open-label trial compares a triplet regimen of trastuzumab deruxtecan (HER2-directed topoisomerase I inhibitor ADC) plus fluoropyrimidine and pembrolizumab with platinum-based chemotherapy plus…
NCT06731478 Registrational - Trial result Spotlight
Stomach and esophageal cancer
EGFR×HER3 bispecific ADC logs 40% responses in PD‑1‑refractory metastatic ESCC
BL‑B01D1 pairs an EGFR‑HER3 bispecific antibody with a cleavable topoisomerase I payload; in the phase 1b NCT05262491 study, 82 heavily pre‑treated ESCC patients received 2.0 or 2.5 mg/kg every 3 weeks. Overall…
NCT05262491 - Trial result
Stomach and esophageal cancer
Regorafenib Benefit Survives Bias-Checks: HR 0.71 in Pooled INTEGRATE Phase 2/3 Gastric Cancer Data
Regorafenib, an oral multikinase inhibitor, was re-examined across the seamless INTEGRATE program—183 refractory gastric or gastro-oesophageal junction cancer patients from phase 2 (with post-progression crossover)…
- New trial
Stomach and esophageal cancer
Phase II RP2 HSV-1 oncolytic virus trial with preoperative FLOT in gastroesophageal cancer
This study investigates whether direct tumor injections of RP2, an HSV-1 oncolytic virus, combined with standard FLOT chemotherapy can improve preoperative tumor eradication in patients with resectable stage II-III…
NCT07059611 Exploratory - New trial
Stomach and esophageal cancer
Phase 3 trial of Tislelizumab PD-1 inhibitor in advanced gastric/gastroesophageal adenocarcinoma.
This multi-center, open-label, randomized study by BeiGene compares subcutaneous versus intravenous tislelizumab—with its immune checkpoint blockade—combined with standard chemotherapy for adults with unresectable or…
NCT07043400 Registrational - New trial
Stomach and esophageal cancer
Phase 1 vvDD-hIL2: Oncolytic vaccinia virus with IL2 expression
This Phase 1 study evaluates vvDD-hIL2 administered via intra-tumoral injection to determine optimal dose and safety in patients with metastatic gastrointestinal and peritoneal tumors (MSI-H and MSS) at AHN West Penn…
NCT07001592 First-in-human - Trial result
Stomach and esophageal cancer
Zanidatamab (HER2 bispecific) + Chemo Drives 76% ORR and 36.5-mo OS in 1L HER2-Positive GEA
Zanidatamab, a dual-epitope HER2-targeted bispecific antibody, was added to CAPOX, FP, or mFOLFOX6 in the single-arm Phase 2 NCT03929666 trial across Canada, Korea, and the USA. Among 46 treatment-naïve,…
NCT03929666 - New trial
Stomach and esophageal cancer
Phase III HLX22 HER2-targeted mAb trial in first-line gastric cancer
This randomized, double-blind phase III study evaluates HLX22 combined with trastuzumab and XELOX versus standard treatment with or without pembrolizumab for HER2-positive locally advanced or metastatic gastric and…
NCT06532006 Registrational - Trial result
Stomach and esophageal cancer
Zanidatamab + chemo posts 76% ORR and 36.5-mo OS as 1L HER2-positive gastro-oesophageal therapy
Zanidatamab, a bispecific HER2-targeted antibody that dimer-locks domains 2 & 4, was combined with CAPOX, FP or mFOLFOX6 in a single-arm, multicentre phase 2 study (NCT03929666). Among 46 treatment-naïve, metastatic…
NCT03929666 - Trial result
Stomach and esophageal cancer
Trastuzumab deruxtecan tops ramucirumab + paclitaxel for 2L HER2-positive gastric cancer, lifting mOS to 14.7 mo
Trastuzumab deruxtecan (T-DXd), a HER2-directed antibody–drug conjugate, was pitted against standard ramucirumab + paclitaxel in the global phase 3 DESTINY-Gastric04 trial (NCT04704934). 494 patients with…
NCT04704934 - Trial result
Stomach and esophageal cancer
NOTCH1-Mutant Esophageal Squamous Cell Carcinoma (ESCC) AchievesGets 18.4 month OS on Tislelizumab—HR 0.35 vs Chemo
Tislelizumab, an anti-PD-1 antibody, was pitted against investigator-choice paclitaxel/docetaxel/irinotecan in the Phase III RATIONALE-302 trial (second-line advanced/metastatic ESCC; NCT03430843). Comprehensive…
NCT03430843 - Trial result
Stomach and esophageal cancer
TAP and CPS Scores Show High Concordance in Predicting Outcomes for Tislelizumab-Treated Gastric and Esophageal Cancers
In a pooled analysis of baseline tissue samples from RATIONALE-305, RATIONALE-302, and RATIONALE-306, PD-L1 expression measured by Tumor Area Positivity (TAP) and Combined Positive Score (CPS) demonstrated…
- Trial result
Stomach and esophageal cancer
Dual HER2-Targeting Zanidatamab Shows Promise in Pre-Treated Gastroesophageal Adenocarcinoma
In this phase 1 trial of 70 heavily pretreated patients with HER2-expressing gastroesophageal adenocarcinoma, zanidatamab monotherapy yielded a confirmed objective response rate of 32.1%, while combining it with…
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.